

## REFERENCES

- [1] Agbandje, M., Jenkins, T.C., McKenna, R., Reszka, A.P., and Neidle, S. (1992). Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives. Journal of medicinal chemistry 35, 1418-1429.
- [2] Alnemri, E.S., Fernandes, T.F., Haldar, S., Croce, C.M., and Litwack, G. (1992). Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B leukemias. Cancer research 52, 491-495.
- [3] Blagosklonny, M.V. (1999). Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia 13, 2031-2035.
- [4] Cervantes, A., Pinedo, H.M., Lankelma, J., and Schuurhuis, G.J. (1988). The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer letters 41, 169-177.
- [5] Cheng, C.C., and Zee-Cheng, R.K. (1983). The design, synthesis and development of a new class of potent antineoplastic anthraquinones. Progress in medicinal chemistry 20, 83-118.
- [6] Chu, E., Voeller, D.M., Morrison, P.F., Jones, K.L., Takechi, T., Maley, G.F., Maley, F., and Allegra, C.J. (1994). The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA. The Journal of biological chemistry 269, 20289-20293.
- [7] DiPaolo JA, A.-S.L. (2004). Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opinion on Biological Therapy 4, 1251-1264.

- [8] Einhorn, L.H., Nagy, C., Werner, K., and Finn, A.L. (1990). Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 8, 731-735.
- [9] Fan, S., Smith, M.L., Rivet, D.J., 2nd, Duba, D., Zhan, Q., Kohn, K.W., Fornace, A.J., Jr., and O'Connor, P.M. (1995). Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer research 55, 1649-1654.
- [10] Fisher, T.C., Milner, A.E., Gregory, C.D., Jackman, A.L., Aherne, G.W., Hartley, J.A., Dive, C., and Hickman, J.A. (1993). bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer research 53, 3321-3326.
- [11] Fojo, T., and Coley, H.M. (2007). The Role of Efflux Pumps in Drug-Resistant Metastatic Breast Cancer: New Insights and Treatment Strategies. Clinical Breast Cancer 7, 749-756.
- [12] Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Zhang, W.W., Owen-Schaub, L.B., and Roth, J.A. (1994). Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer research 54, 2287-2291.
- [13] Han, J., Flemington, C., Houghton, A.B., Gu, Z., Zambetti, G.P., Lutz, R.J., Zhu, L., and Chittenden, T. (2001). Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proceedings of the National Academy of Sciences of the United States of America 98, 11318-11323.



- [14] Hawkins, D.S., Demers, G.W., and Galloway, D.A. (1996). Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer research 56, 892-898.
- [15] Hunger, S., Di Gaspero, G., Mohring, S., Bellin, D., Schafer-Pregl, R., Borchardt, D.C., Durel, C.E., Werber, M., Weisshaar, B., Salamini, F., and Schneider, K. (2003). Isolation and linkage analysis of expressed disease-resistance gene analogues of sugar beet (*Beta vulgaris L.*). Genome / National Research Council Canada = Genome / Conseil national de recherches Canada 46, 70-82.
- [16] Juliano, R.L., and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et biophysica acta 455, 152-162.
- [17] Kaur, P., McDougall, J.K., and Cone, R. (1989). Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames. The Journal of general virology 70 ( Pt 5), 1261-1266.
- [18] Krapcho, A.P., Getahun, Z., Avery, K.L., Jr., Vargas, K.J., Hacker, M.P., Spinelli, S., Pezzoni, G., and Manzotti, C. (1991). Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]5,8-dihydroxyanthracene-9,10-diones. Journal of medicinal chemistry 34, 2373-2380.
- [19] Kuo, M.T. (2009). Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling 11, 99-133.

- [20] Licht, T., Haskins, M., Henthorn, P., Kleiman, S.E., Bodine, D.M., Whitwam, T., Puck, J.M., Gottesman, M.M., and Melniczek, J.R. (2002). Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proceedings of the National Academy of Sciences of the United States of America 99, 3123-3128.
- [21] Loehrer, P.J., and Einhorn, L.H. (1984). Drugs five years later. Cisplatin. Annals of internal medicine 100, 704-713.
- [22] Lu, Q.L., Elia, G., Lucas, S., and Thomas, J.A. (1993). Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. International journal of cancer. Journal international du cancer 53, 29-35.
- [23] Lutzker, S.G., and Levine, A.J. (1996). A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature medicine 2, 804-810.
- [24] Mannervik, B., and Danielson, U.H. (1988). Glutathione transferases--structure and catalytic activity. CRC critical reviews in biochemistry 23, 283-337.
- [25] McEvoy, J.D., Crooks, S.R., Elliott, C.T., McCaughey, W.J., and Kennedy, D.G. (1994). Origin of chlortetracycline in pig tissue. The Analyst 119, 2603-2606.
- [26] McKnight, R.E., Zhang, J., and Dixon, D.W. (2004). Binding of a homologous series of anthraquinones to DNA. Bioorganic & medicinal chemistry letters 14, 401-404.
- [27] Momparler, R.L., Karon, M., Siegel, S.E., and Avila, F. (1976). Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer research 36, 2891-2895.

- [28] Muggia, F.M., and Green, M.D. (1991). New anthracycline antitumor antibiotics. Critical reviews in oncology/hematology 11, 43-64.
- [29] Nakanishi, F., Nagasawa, Y., Kabaya, Y., Sekimoto, H., and Shimomura, K. (2005). Characterization of lucidin formation in Rubia tinctorum L. Plant physiology and biochemistry : PPB / Societe francaise de physiologie vegetale 43, 921-928.
- [30] Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijs, H.J., and Moens, A.L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology 52, 1213-1225.
- [31] Ossowski, L., and Aguirre-Ghiso, J.A. (2000). Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Current opinion in cell biology 12, 613-620.
- [32] Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA: a cancer journal for clinicians 55, 74-108.
- [33] Proskuryakov, S.Y., Konoplyannikov, A.G., and Gabai, V.L. (2003). Necrosis: a specific form of programmed cell death? Experimental cell research 283, 1-16.
- [34] Ruiz, J., Rodriguez, V., Cutillas, N., Lopez, G., and Bautista, D. (2008). Acetonimine and 4-imino-2-methylpentan-2-amino platinum(II) complexes: synthesis and in vitro antitumor activity. Inorganic chemistry 47, 10025-10036.
- [35] Scanlon, K.J., Kashani-Sabet, M., Tone, T., and Funato, T. (1991). Cisplatin resistance in human cancers. Pharmacology & therapeutics 52, 385-406.
- [36] Scheffner, M. (1998). Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacology & therapeutics 78, 129-139.
- [37] Siddik, Z.H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279.


- [38] Ueda, K., Cornwell, M.M., Gottesman, M.M., Pastan, I., Roninson, I.B., Ling, V., and Riordan, J.R. (1986). The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochemical and biophysical research communications 141, 956-962.
- [39] Vousden, K.H. (2002). Switching from life to death: the Miz-ing link between Myc and p53. Cancer cell 2, 351-352.
- [40] Yu, J., and Zhang, L. (2008). PUMA, a potent killer with or without p53. Oncogene 27 Suppl 1, S71-83.
- [41] Zamble, D.B., and Lippard, S.J. (1995). Cisplatin and DNA repair in cancer chemotherapy. Trends in biochemical sciences 20, 435-439.
- [42] zur Hausen, H. (1996). Papillomavirus infections--a major cause of human cancers. Biochimica et biophysica acta 1288, F55-78.

## APPENDICES





<sup>1</sup>H-Spectrum of compound 1

Appendix A1





<sup>1</sup>H-Spectrum of compound 2

Appendix B1





<sup>13</sup>C-Spectrum of compound 2

Appendix B2




<sup>1</sup>H-Spectrum of compound 3

Appendix C1



<sup>13</sup>C-Spectrum of compound 3

Appendix C2





printed: 04/25/2013 03:56:23

MS-Spectrum of compound 3


Appendix C3

1H NMR (CDCl<sub>3</sub>, 400 MHz) δ ppm: 7.90 (s, 1H, H-1), 7.75 (d, 1H, H-2), 7.65 (d, 1H, H-3), 7.55 (d, 1H, H-4), 7.45 (d, 1H, H-5), 7.35 (d, 1H, H-6), 7.25 (d, 1H, H-7), 7.15 (d, 1H, H-8), 7.05 (d, 1H, H-9), 6.95 (d, 1H, H-10), 6.85 (d, 1H, H-11), 6.75 (d, 1H, H-12), 6.65 (d, 1H, H-13), 6.55 (d, 1H, H-14), 6.45 (d, 1H, H-15), 6.35 (d, 1H, H-16), 6.25 (d, 1H, H-17), 6.15 (d, 1H, H-18), 6.05 (d, 1H, H-19), 5.95 (d, 1H, H-20), 5.85 (d, 1H, H-21), 5.75 (d, 1H, H-22), 5.65 (d, 1H, H-23), 5.55 (d, 1H, H-24), 5.45 (d, 1H, H-25), 5.35 (d, 1H, H-26), 5.25 (d, 1H, H-27), 5.15 (d, 1H, H-28), 5.05 (d, 1H, H-29), 4.95 (d, 1H, H-30), 4.85 (d, 1H, H-31), 4.75 (d, 1H, H-32), 4.65 (d, 1H, H-33), 4.55 (d, 1H, H-34), 4.45 (d, 1H, H-35), 4.35 (d, 1H, H-36), 4.25 (d, 1H, H-37), 4.15 (d, 1H, H-38), 4.05 (d, 1H, H-39), 3.95 (d, 1H, H-40), 3.85 (d, 1H, H-41), 3.75 (d, 1H, H-42), 3.65 (d, 1H, H-43), 3.55 (d, 1H, H-44), 3.45 (d, 1H, H-45), 3.35 (d, 1H, H-46), 3.25 (d, 1H, H-47), 3.15 (d, 1H, H-48), 3.05 (d, 1H, H-49), 2.95 (d, 1H, H-50), 2.85 (d, 1H, H-51), 2.75 (d, 1H, H-52), 2.65 (d, 1H, H-53), 2.55 (d, 1H, H-54), 2.45 (d, 1H, H-55), 2.35 (d, 1H, H-56), 2.25 (d, 1H, H-57), 2.15 (d, 1H, H-58), 2.05 (d, 1H, H-59), 1.95 (d, 1H, H-60), 1.85 (d, 1H, H-61), 1.75 (d, 1H, H-62), 1.65 (d, 1H, H-63), 1.55 (d, 1H, H-64), 1.45 (d, 1H, H-65), 1.35 (d, 1H, H-66), 1.25 (d, 1H, H-67), 1.15 (d, 1H, H-68), 1.05 (d, 1H, H-69), 0.95 (d, 1H, H-70), 0.85 (d, 1H, H-71), 0.75 (d, 1H, H-72), 0.65 (d, 1H, H-73), 0.55 (d, 1H, H-74), 0.45 (d, 1H, H-75), 0.35 (d, 1H, H-76), 0.25 (d, 1H, H-77), 0.15 (d, 1H, H-78), 0.05 (d, 1H, H-79).



<sup>1</sup>H-Spectrum of compound 4

Appendix D1



$^{13}\text{C}$ -Spectrum of compound 4

Appendix D2

D:\DATA\Uplpt\tookVAQ series II\25-04-56 11\0\_G3\1

Comment 1 25-04-56 11

Comment 2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296


297

</

```
beam=5
data_to_load=0
archive_directory=/archive/directories/
export /home/pcuser/nomysys/data
Sweep_start=550000
Sweep_end=5500000
Time=10:00:00-26-104526
Title: PROTON_01

#Basic impedance setup
#Device: VNA-101
ambient_temperature=
```


Port1: delay=1.000 sec  
Port2: 0.000 sec  
Line: 1.000 sec  
Width: 500.000 Hz  
S\_repetitions: 1  
S\_start: 1.000 sec  
S\_end: 1.000 sec  
Data\_resampling: 1000000000  
FI\_size: 32768  
Total\_time: 0 min



### <sup>1</sup>H-Spectrum of compound 5

## Appendix E1

အမှုပါမ်..... ၃၇၁ . ၂၉၅၆




$^{13}\text{C}$ -Spectrum of compound 5

Appendix E2


D:\DATA\Upl\took\AQ series II\25-04-56 12-20\_G4A1

Comment 1 25-04-56\_32-2  
Comment 2

Intens. [a.u.]




Phenyl  
 Data Collected on:  
 mercury4  
 Andocs 4T-75  
 /export/home/cpuser/vnmrsys/date  
 Sample directory:  
 -/ak03\_2010-11-12  
 file: PR07M\_01  
 Pulse Sequence: 32pul  
 Solvent: CDCl<sub>3</sub>  
 Ambient temperature  
 Polar., delay 1.000 sec  
 Pulse 45.0 degrees  
 Acq. time 1.595 sec  
 Scan 0.220 sec  
 3 repetitions  
 OBSERVE 1H, 300.622579 MHz  
 DATA PROCESSING  
 27 Sept 2010  
 Total time 9 min




<sup>1</sup>H-Spectrum of compound 6

Appendix F1



### <sup>13</sup>C-Spectrum of compound 6



## Appendix F2



### MS-Spectrum of compound 6


### Appendix F3

0ethyl-07  
 Data collected on:  
 Bruker DRX-400 spectrometer  
 Chemical shift (ppm)  
 TMS reference/CDCl<sub>3</sub>/TMS/CDCl<sub>3</sub>  
 Sample direction:  
 99.001\_2013-06-24-104225  
 File: PROTON\_01  
 Pulse Sequence: zgppr1d  
 Solvent: CDCl<sub>3</sub>  
 Ambient temperature  
 Relax. time: 1.000 sec  
 Pulse: 9.5 degrees  
 Avg.: 1.00%  
 SW1: 4000.0 Hz  
 FID length: 16384 points  
 QSPY: 1.1 159.6626479 MHz  
 DATA PROCESSING:  
 1.422.1.1.8  
 Total time: 6 min



<sup>1</sup>H-Spectrum of compound 7

### Appendix G1



$^{13}\text{C}$ -Spectrum of compound 7


Appendix G2


D:\DATA\Up\p\tak\AQ series II\25-04-56 14-2\0\_G6\1

Comment 1 25-04-56 14-2

Comment 2


Intens. [3 u.]  $\times 10^4$






<sup>1</sup>H-Spectrum of compound 8

Appendix H1





$^{13}\text{C}$ -Spectrum of compound 8

Appendix H2




MS-Spectrum of compound 8

Appendix H3



<sup>1</sup>H-Spectrum of compound 9

Appendix I1





$^{13}\text{C}$ -Spectrum of compound 9

Appendix I2

D:\DATA\Up\p'took\ID\0\_G5\1

Comment 1  
Comment 2



Intens. [a.u.]



MS-Spectrum of compound 9


Appendix I3

1H NMR  
 CDCl<sub>3</sub>, 400 MHz  
 δ, ppm: 7.69 (d, J = 7.9 Hz, 1H, H<sub>10</sub>), 7.43 (d, J = 7.9 Hz, 1H, H<sub>11</sub>), 7.35 (t, J = 7.9 Hz, 1H, H<sub>12</sub>), 7.25 (t, J = 7.9 Hz, 1H, H<sub>13</sub>), 7.14 (s, 1H, H<sub>14</sub>), 6.92 (s, 1H, H<sub>15</sub>), 6.83 (s, 1H, H<sub>16</sub>), 6.78 (s, 1H, H<sub>17</sub>), 6.69 (s, 1H, H<sub>18</sub>), 3.79 (s, 3H, OMe).  
 IR (KBr): 3029, 2926, 1719, 1605, 1510, 1454, 1375, 1254, 1171, 1054, 800 cm<sup>-1</sup>.  
 ESI-MS: m/z 480 [M + Na]<sup>+</sup>.  
 HR-ESI-MS: m/z 479.1625 [M + H]<sup>+</sup> (calcd for C<sub>27</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>S, 479.1625).




<sup>1</sup>H-Spectrum of compound 10

Appendix J1




$^{13}\text{C}$ -Spectrum of compound 10

Appendix J2




MS-Spectrum of compound 10

Appendix J3




<sup>1</sup>H-Spectrum of compound 11

Appendix K1



$^{13}\text{C}$ -Spectrum of compound 11



Appendix K2



MS-Spectrum of compound 11


Appendix K3

Fe10H-6  
 Data Collected on:  
 mercury100-mercury100  
 Serial Number: 147  
 /var/opt/maay/cluster/nmrssvdata  
 Sample directory:  
 ssst001\_2011-05-25  
 File: FPD0H1\_01  
 Pulse Sequence: N1P1  
 Solvent: CDCl<sub>3</sub>  
 Ambient temperature  
 Relax. delay 1.000 sec  
 Pulse 45.0 degrees  
 Acq. time 1.305 sec  
 width 6389.8 Hz  
 8 scans  
 OBSERVE: H1, 393.82629 MHz  
 DATA PROCESSING:  
 t1 size 32768  
 total time 8 min



<sup>1</sup>H-Spectrum of compound 12

Appendix L1





$^{13}\text{C}$ -Spectrum of compound 12

Appendix L2

D:\DATA\Up\p'took\G0\_G8\1

Comment 1 G  
Comment 2

Intens. [a.u.]





printed: 03/30/2013 01:37:02

MS-Spectrum of compound 12


Appendix L3

Tetraethylene  
 Data Collector: m  
 DataCvrt300-mercury.m  
 Archive directory:  
 /opt/pic300/cvrt300/chem3d/data  
 Scan directory:  
 /opt/pic300/chem3d/data  
 System: 2011-04-23  
 File: PROTON\_01  
 Pulse Sequence: SW11  
 Solvent: CDCl<sub>3</sub>  
 Ambient temperature  
 Proton width: 1.000 Hz  
 Pulse: 45.0 degrees  
 Acq. time: 1.957 sec  
 Width: 6.000 Hz  
 N repetitions: 8  
 DPPMPC: 3.33 ppm, 6579 MHz  
 DATA PROCESSING:  
 1) Vite v3.0E  
 Total time: 8 min



<sup>1</sup>H-Spectrum of compound 13

### Appendix M1



$^{13}\text{C}$ -Spectrum of compound 13

Appendix M2

D:\DATA\Up\p'took\H310\_G9\1

Comment 1 H3  
Comment 2

Intens. [a.u.]

8000


6000

4000

2000

0

241.42:





592.330

m/z

printed: 03/30/2013 01:37:47



### MS-Spectrum of compound 13

Appendix M3



<sup>1</sup>H-Spectrum of compound 14

Appendix N1



<sup>13</sup>C-Spectrum of compound 14

Appendix N2


D:\DATA\Up\p'took\l0\_G101

Comment 1  
Comment 2

Intens [a.u.]

2000  
1500  
1000  
500  
0

410.257  
416.276




m/z

printed: 03/30/2013 01:38:33


MS-Spectrum of compound 14

Appendix N3




### <sup>1</sup>H-Spectrum of compound 15

## Appendix O1



$^{13}\text{C}$ -Spectrum of compound 15

Appendix O2



### MS-Spectrum of compound 15

## Appendix O3

## **Postdoctoral fellowship recommendation for Supranee Sangthong**

It is my pleasure to recommend Miss. Supranee Sangthong for your postdoctoral position as I have gotten to know Miss. Sangthong over 6 years as one of my most active and effective participants in daily research.

Miss. Sangthong's talents have repeatedly impressed many of us as she was the student who raised the serious and challenging issues that pushed the dialogue to a more in depth level. I am confident she can be an exceptional performer since she is an outstanding researcher. She was also the strongest student and a review of her academic publications reveals her performance was repeated across her two years in master's degree and four years in doctorate. Intellectually, she is clearly a star and she's a very nice and genuine person as well. It has been our pleasure working with her.

I strongly recommend Miss. Sangthong to you and without reservation. She will be a wonderful addition to your chambers. If I can assist in your review of her application, please contact me.

Sincerely yours,

Assoc. Prof. Dr. Nattaya Ngamrochanavanich  
Department of Chemistry, Chulalongkorn University  
Phone: +66-2-2187635  
Fax: Phone: +66-2-2187635  
email: [nattaya.n@chula.ac.th](mailto:nattaya.n@chula.ac.th)

## VITA

Supranee Sangthong was born in Nakornsawan, Thailand on January 25, 1984. She received Bachelor Degree of Science in Microbiology from Khonkaen University in 2006 and graduated the Master Degree with of Science in Biotechnology from Chulalongkorn University in 2008. She has become a student in Doctor of Philosophy of Chulalongkorn University in Biotechnology, Faculty of Science.

